Effective January 24, 2022, the FDA updated the Emergency Use Authorization (EUA) fact sheets for two COVID-19 monoclonal antibody treatments: bamlanivimab plus etesevimab (Eli Lilly) and casirivimab plus imdevimab (Regeneron, also known as REGEN-COV). Neither of these treatments are authorized for use anywhere in the U.S. due to their ineffectiveness against the dominant Omicron variant. Sites are directed to immediately stop administering these therapeutics as they do not retain EUA.

Ph: (443) 281-9157

Fax: (410) 582-8728

801 Landmark Dr.
Glen Burnie, MD 21061
Contact Us

Mon-Fri: 8:30AM-6:30PM

Sat: 9:00AM-2:00PM
Christopher F.

Christopher F.

Trieu Bao is the definition of what a pharmacist should be. The personal care taken in filling your medications and working with you through problems with insurance or your doctor is second to none. Not only is he a nice guy, he actually cares about your health and...
Christopher F.

Cathy S.

There’s something to be said for customer service. Very nice people and not knocking the big chain stores, but here, you don’t feel like a number.